Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open label study to assess the efficacy, safety and tolerability of Cozaar plus (losartan potassium 50mg/hydrochlorothiazide 12.5mg) possibly titrated up to Cozaar plus-F (losartan potassium 100mg/hydrochlorothiazide 25mg) in patients with essential hypertension

Next Previous
X
Search
Trial Profile

An open label study to assess the efficacy, safety and tolerability of Cozaar plus (losartan potassium 50mg/hydrochlorothiazide 12.5mg) possibly titrated up to Cozaar plus-F (losartan potassium 100mg/hydrochlorothiazide 25mg) in patients with essential hypertension

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 19 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Losartan/hydrochlorothiazide (Primary)
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Sponsors Organon

    • Most Recent Events

    • 18 May 2007 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top